Charles River Laboratories International Inc. has entered into a gene therapy contract development and manufacturing organization $(CDMO)$ collaboration with Gazi University Faculty of Medicine. The partnership aims to advance rare disease research at Gazi University by providing plasmid DNA for AAV production and in vitro efficacy studies. Through this collaboration, Charles River will supply off-the-shelf, research-grade AAV plasmids, produced with animal component-free methods, to support early-stage gene therapy programs. This initiative is expected to accelerate the development of transformative therapies for rare diseases, leveraging Charles River’s expertise in cell and gene therapy manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121488189) on January 21, 2026, and is solely responsible for the information contained therein.